Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck's Q3 earnings soar, driven by Keytruda's record sales, reaching $8B for the first time. Despite patent expiration in 2028, Merck plans to cut $3B in costs by 2027. Gardasil sales drop in China, but meet expectations. Animal health segment surges 16% with strong livestock product demand.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.